Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-658-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.34 million
Profitability
Miscellaneous
Employees332
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.25. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.75 million. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
7 brokerages have issued twelve-month price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $30.00. On average, they expect Karyopharm Therapeutics' share price to reach $18.7143 in the next twelve months. This suggests a possible upside of 227.7% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.
What is the consensus analysts' recommendation for Karyopharm Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (3/2/2019)
- 2. HC Wainwright analysts commented, "We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and an estimated early stage pipeline value of $0.86/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x." (2/27/2019)
Has Karyopharm Therapeutics been receiving favorable news coverage?
Media headlines about KPTI stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Karyopharm Therapeutics.
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Heron Therapeutics (HRTX), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Opko Health (OPK), Corcept Therapeutics (CORT), Athenex (ATNX), Phibro Animal Health (PAHC), Eidos Therapeutics (EIDX), Epizyme (EPZM), OrganiGram (OGI), Dicerna Pharmaceuticals (DRNA) and Alder Biopharmaceuticals (ALDR).
What other stocks do shareholders of Karyopharm Therapeutics own?
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
- Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
- Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
- Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)
Who are Karyopharm Therapeutics' major shareholders?
Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (13.86%), BlackRock Inc. (6.87%), Candriam Luxembourg S.C.A. (3.07%), FMR LLC (2.52%), Emerald Advisers LLC (2.48%) and Emerald Mutual Fund Advisers Trust (2.26%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.
Which major investors are selling Karyopharm Therapeutics stock?
KPTI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Federated Investors Inc. PA, First Trust Advisors LP, Citigroup Inc., BlackRock Inc., Schonfeld Strategic Advisors LLC, Charles Schwab Investment Management Inc. and Northern Trust Corp. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.
Which major investors are buying Karyopharm Therapeutics stock?
KPTI stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, First Midwest Bank Trust Division, Wellington Management Group LLP, Connor Clark & Lunn Investment Management Ltd., Marshall Wace North America L.P. and Marshall Wace North America L.P.. View Insider Buying and Selling for Karyopharm Therapeutics.
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $5.71.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $347.51 million and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.
What is Karyopharm Therapeutics' official website?
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
